{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045556","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.440429+00:00","generated_at":"2026-05-22T06:52:22.076196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%","bullets":["Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.","Royalty revenue from GSK was $61.3M, largely flat year-over-year.","U.S. net product sales from IST (GIAPREZA, XACDURO, XERAVA) grew 52% to $26.4M; total net product sales $30.3M.","Income from operations rose 61% to $41.4M; cash and equivalents $319.1M at quarter end.","Zoliflodacin NDA on track for H1 2025 filing; ZEVTERA U.S. launch expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045556","json":"https://secwatch.observer/filing/0001104659-25-045556.json","markdown":"https://secwatch.observer/filing/0001104659-25-045556.md","text":"https://secwatch.observer/filing/0001104659-25-045556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/0001104659-25-045556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/tm2514212d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:52:22.076196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}